422 related articles for article (PubMed ID: 26738756)
21. [Golimumab Therapy in Ulcerative Colitis].
Moon W
Korean J Gastroenterol; 2016 Feb; 67(2):64-73. PubMed ID: 26907481
[TBL] [Abstract][Full Text] [Related]
22. Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis.
O'Connell J; Rowan C; Stack R; Harkin G; Parihar V; Chan G; Breslin N; Cullen G; Dunne C; Egan L; Harewood G; Leyden J; MacCarthy F; MacMathuna P; Mahmud N; McKiernan S; McNamara D; Mulcahy H; Murray F; O'Connor A; O'Toole A; Patchett S; Ryan B; Sheridan J; Slattery E; Doherty G; Kevans D
Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1019-1026. PubMed ID: 29878945
[TBL] [Abstract][Full Text] [Related]
23. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
[TBL] [Abstract][Full Text] [Related]
24. Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study.
Magro F; Lopes S; Silva M; Coelho R; Portela F; Branquinho D; Correia L; Fernandes S; Cravo M; Caldeira P; Sousa HT; Patita M; Lago P; Ramos J; Afonso J; Redondo I; Machado P; Cornillie F; Lopes J; Carneiro F;
J Crohns Colitis; 2019 Oct; 13(11):1387-1393. PubMed ID: 30989180
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study).
Hibi T; Imai Y; Senoo A; Ohta K; Ukyo Y
J Gastroenterol; 2017 Oct; 52(10):1101-1111. PubMed ID: 28324167
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study.
Fumery M; Nancey S; Filippi J; Altwegg R; Hébuterne X; Boshetti G; Barraud M; Meynier J; Paul S; Roblin X
Aliment Pharmacol Ther; 2023 Jun; 57(11):1290-1298. PubMed ID: 36849714
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness and Safety of Golimumab in Treating Outpatient Ulcerative Colitis: A Real-Life Prospective, Multicentre, Observational Study in Primary Inflammatory Bowel Diseases Centers.
Tursi A; Allegretta L; Buccianti N; Della Valle N; Elisei W; Forti G; Faggiani R; Gallina S; Hadad Y; Larussa T; Lauria A; Luzza F; Lorenzetti R; Mocci G; Penna A; Polimeni N; Pranzo G; Ricciardelli C; Zampaletta C; Picchio M
J Gastrointestin Liver Dis; 2017 Sep; 26(3):239-244. PubMed ID: 28922435
[TBL] [Abstract][Full Text] [Related]
28. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
Feagan BG; Sands BE; Sandborn WJ; Germinaro M; Vetter M; Shao J; Sheng S; Johanns J; Panés J;
Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):307-320. PubMed ID: 36738762
[TBL] [Abstract][Full Text] [Related]
29. Golimumab for moderately to severely active ulcerative colitis.
Kedia S; Ahuja V; Makharia GK
Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
[TBL] [Abstract][Full Text] [Related]
30. Identification of Target Golimumab Levels in Maintenance Therapy of Crohn's Disease and Ulcerative Colitis Associated With Mucosal Healing.
Boland K; Greener T; Kabakchiev B; Stempak J; Tessolini J; Li R; Soriano J; Croitoru K; Nguyen G; Steinhart AH; Weizman AV; Silverberg MS
Inflamm Bowel Dis; 2020 Apr; 26(5):766-773. PubMed ID: 31676891
[TBL] [Abstract][Full Text] [Related]
31. Golimumab: clinical update on its use for ulcerative colitis.
Gilardi D; Fiorino G; Allocca M; Bravatà I; Danese S
Drugs Today (Barc); 2015 Mar; 51(3):171-84. PubMed ID: 25876561
[TBL] [Abstract][Full Text] [Related]
32. Initial experience with golimumab in clinical practice for ulcerative colitis.
Castro-Laria L; Argüelles-Arias F; García-Sánchez V; Benítez JM; Fernández-Pérez R; Trapero-Fernández AM; Gallardo-Sánchez F; Pallarés-Manrique H; Gómez-García M; Cabello-Tapia MJ; Talavera-Fabuel A; Bejarano-García A; Leo-Carnerero E; Hernández-Martínez Á; Caunedo-Álvarez Á; Herrerías-Gutiérrez JM
Rev Esp Enferm Dig; 2016 Mar; 108(3):129-32. PubMed ID: 26786341
[TBL] [Abstract][Full Text] [Related]
33. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.
Adedokun OJ; Sandborn WJ; Feagan BG; Rutgeerts P; Xu Z; Marano CW; Johanns J; Zhou H; Davis HM; Cornillie F; Reinisch W
Gastroenterology; 2014 Dec; 147(6):1296-1307.e5. PubMed ID: 25173754
[TBL] [Abstract][Full Text] [Related]
34. Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic Data.
Philip G; Cornillie F; Adedokun JO; Melsheimer R; Rutgeerts P; Colombel JF; Marano C
J Crohns Colitis; 2019 Sep; 13(10):1257-1264. PubMed ID: 30847474
[TBL] [Abstract][Full Text] [Related]
35. Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis.
Papamichael K; Baert F; Tops S; Assche GV; Rutgeerts P; Vermeire S; Gils A; Ferrante M
J Crohns Colitis; 2017 Jan; 11(1):53-59. PubMed ID: 27402915
[TBL] [Abstract][Full Text] [Related]
36. Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis.
Taxonera C; Iborra M; Bosca-Watts MM; Rubio S; Nantes Ó; Higuera R; Bertoletti F; Martínez-Montiel P; Sierra-Ausin M; Manceñido N; Lázaro Pérez-Calle J; Algaba A; Olivares D; Alba C
Curr Med Res Opin; 2019 Jul; 35(7):1297-1304. PubMed ID: 30722703
[No Abstract] [Full Text] [Related]
37. Neutrophil gelatinase B-associated lipocalin and matrix metalloproteinase-9 complex as a surrogate serum marker of mucosal healing in ulcerative colitis.
de Bruyn M; Arijs I; Wollants WJ; Machiels K; Van Steen K; Van Assche G; Ferrante M; Rutgeerts P; Vermeire S; Opdenakker G
Inflamm Bowel Dis; 2014 Jul; 20(7):1198-207. PubMed ID: 24871805
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.
Thorlund K; Druyts E; Toor K; Mills EJ
Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):693-700. PubMed ID: 25763862
[TBL] [Abstract][Full Text] [Related]
39. Golimumab for the treatment of ulcerative colitis.
Flamant M; Paul S; Roblin X
Expert Opin Biol Ther; 2017 Jul; 17(7):879-886. PubMed ID: 28472597
[TBL] [Abstract][Full Text] [Related]
40. Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab.
Reinisch W; Colombel JF; Gibson PR; Rutgeerts P; Sandborn WJ; Tarabar D; Huyck S; Khalifa A; Marano C; Philip G; Yao R; Zhang H; Cornillie F
Inflamm Bowel Dis; 2019 Jan; 25(1):163-171. PubMed ID: 29982631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
